3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Conditions
Smoldering Multiple Myeloma
2
Prostatic Neoplasms
2
Monoclonal Gammopathy of Undetermined Significance
2
Uterine Cervical Neoplasms
1
Thrombocythemia, Essential
1
Stomach Neoplasms
1
Psychological Well-Being
1
Primary Myelofibrosis
1
Polycythemia Vera
1
Neoplasms
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Motor Activity
1
Lung Neoplasms
1
Locally Advanced Cervical Cancer
1
Esophageal Neoplasms
1
Castration Sensitive Prostate Cancer
1
Interventions
Oxaliplatin
42
Fluorouracil
27
Capecitabine
24
pembrolizumab
21
S 1 (combination)
19
Paclitaxel
19
Leucovorin
16
Nivolumab
13
sintilimab
12
Drug Therapy
12
Docetaxel
12
tislelizumab
11
Trastuzumab
10
Cisplatin
10
Irinotecan
8
Bevacizumab
8
trastuzumab deruxtecan
7
spartalizumab
7
fludarabine
7
XELOX
7
Surgical Procedures, Operative
7
Radiotherapy
7
Cyclophosphamide
7
Biopsy
7
disitamab vedotin
6
Hyperthermic Intraperitoneal Chemotherapy
6
lenvatinib
5
apatinib
5
Specimen Handling
5
Ramucirumab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Stomach Neoplasms
×
Curcumin
×
Clear all
NCT04871412
2026-01-30
POISE
Ottawa Hospital Research Institute
Phase 3
Recruiting
20 enrolled